1.305.989.1513 info@nexienbiopharma.com

Nexien’s Drug Development Activities

Nexien is researching the use of cannabinoid receptor modulators, terpenes, and other ingredients for:

Nexien BioPharma’s drug development strategy consists of:

  • The acute treatment during exposure to organophosphorus nerve agents , including sarin gas.
  • The treatment of various symptoms related to myotonic and muscular diseases such as dystrophia diseases.
  • The treatment of  various symptoms related to ipidosis, which are genetic disorders which are characterized by defects of the digestive system that impair the way the body uses dietary fat.
  • The treatment of  various symptoms related to lipofuscinosis, in particular neural ceroid lipofuscinosis and macular degeneration associated with lipofuscinosis, which is any disorder associated with the abnormal storage of lipofuscins. Lipofuscins is a yellow to brownish pigment granule found in the muscle, heart, liver, kidney, adrenal, retina and nerve cells undergoing slow regressive changes and accumulating in lysomes with age.
  • The treatment of restless legs syndrome. Restless leg syndrome (RLS) otherwise known as Willis-Ekbom Disease and Wittmaack-Ekbom Syndrome is a term used to describe a neurological sensory disorder that also interferes with sleep and is thus also considered a sleep disorder.
  • Sexual health affecting both males and females. Male sexual health issues or dysfunction issues include male erectile dysfunction, ejaculatory disorders, such as premature ejaculation, anorgasmia (inability to achieve orgasm) and desire disorders such as hypoactive sexual desire disorder (lack of interest in sex). Female sexual health issues or dysfunction issues can be defined as the difficulty or inability of a woman to find satisfaction in sexual expression.